A new study suggests that antidepressants used by pregnant women may increase their offspring’s risk of type 2 diabetes and obesity later in life. Certain antidepressants, known as selective serotonin reuptake inhibitors (SSRIs), have already been linked to potential birth defects in the children of pregnant users.
The research, conducted by scientists at McMaster University in Ontario, Canada, was designed to find a connection between the use of antidepressants and the development of fatty liver in the baby. The study demonstrated an “increased fat accumulation and inflammation of the liver of the adult offspring, raising new concerns about the long-term metabolic complications in children born to women who take SSRI antidepressants during pregnancy.”
The scientists are now trying to find out how these problems occur by researching the chemical reactions that these drugs cause during pregnancy. The researchers think the study may help with the identification of a high-risk group or groups that may require future medication or interventions to prevent adverse metabolic outcomes.
Prior to the study, there was a known link between SSRIs and obesity in adults, but use during pregnancy was not known to increase the risk of metabolic disturbances. Additionally, serious birth defects have been linked to SSRI use by pregnant women in their children, such as the newborn lung disorder, pulmonary hypertension, and a brain defect known as Chiari 1 malformation.
To discuss a potential case for your child or family member related to SSRIs, request a free consultation and claim evaluation with our law firm. We are currently pursuing cases on behalf of children injured by SSRIs taken by their mothers during pregnancy.